Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2014 | Pages:
44 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Valeant Pharmaceuticals International, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Valeant Pharmaceuticals International, Inc. - Product Pipeline Review - 2014', provides an overview of the Valeant Pharmaceuticals International, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Valeant Pharmaceuticals International, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Valeant Pharmaceuticals International, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Valeant Pharmaceuticals International, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Valeant Pharmaceuticals International, Inc.'s pipeline products Reasons to buy - Evaluate Valeant Pharmaceuticals International, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Valeant Pharmaceuticals International, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Valeant Pharmaceuticals International, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Valeant Pharmaceuticals International, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Valeant Pharmaceuticals International, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Valeant Pharmaceuticals International, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Valeant Pharmaceuticals International, Inc. Snapshot 5 Valeant Pharmaceuticals International, Inc. Overview 5 Key Information 5 Key Facts 5 Valeant Pharmaceuticals International, Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 Valeant Pharmaceuticals International, Inc. - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Pipeline Products - Partnered Products 10 Partnered Products/Combination Treatment Modalities 11 Pipeline Products - Out-Licensed Products 12 Out-Licensed Products/Combination Treatment Modalities 13 Valeant Pharmaceuticals International, Inc. - Pipeline Products Glance 14 Valeant Pharmaceuticals International, Inc. - Late Stage Pipeline Products 14 Phase III Products/Combination Treatment Modalities 14 Valeant Pharmaceuticals International, Inc. - Clinical Stage Pipeline Products 15 Phase II Products/Combination Treatment Modalities 15 Phase I Products/Combination Treatment Modalities 16 Valeant Pharmaceuticals International, Inc. - Drug Profiles 17 brimonidine tartrate 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 Product-55394 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 CB-0301 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 IDP-118 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 JNJ-10229570-AAA 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 Product-10156 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 Product-49778 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 Valeant Pharmaceuticals International, Inc. - Pipeline Analysis 26 Valeant Pharmaceuticals International, Inc. - Pipeline Products by Target 26 Valeant Pharmaceuticals International, Inc. - Pipeline Products by Route of Administration 27 Valeant Pharmaceuticals International, Inc. - Pipeline Products by Molecule Type 28 Valeant Pharmaceuticals International, Inc. - Pipeline Products by Mechanism of Action 29 Valeant Pharmaceuticals International, Inc. - Recent Pipeline Updates 30 Valeant Pharmaceuticals International, Inc. - Dormant Projects 32 Valeant Pharmaceuticals International, Inc. - Discontinued Pipeline Products 33 Discontinued Pipeline Product Profiles 33 (bupropion hydrobromide + selective serotonin reuptake inhibitor) 33 ATON-004 33 CVTE-002 33 ezogabine 34 IDP-107 34 IDP-109 34 IDP-115 34 MC-5 34 pegaptanib sodium 34 RUS-350 34 taribavirin hydrochloride 35 tiazofurin 35 tramadol hydrochloride 35 Valeant Pharmaceuticals International, Inc. - Company Statement 36 Valeant Pharmaceuticals International, Inc. - Locations And Subsidiaries 37 Head Office 37 Other Locations & Subsidiaries 37 Valeant Pharmaceuticals International, Inc. - Key Manufacturing Facilities 42 Appendix 43 Methodology 43 Coverage 43 Secondary Research 43 Primary Research 43 Expert Panel Validation 43 Contact Us 44 Disclaimer 44
List of Tables Valeant Pharmaceuticals International, Inc., Key Information 5 Valeant Pharmaceuticals International, Inc., Key Facts 5 Valeant Pharmaceuticals International, Inc. - Pipeline by Indication, 2014 7 Valeant Pharmaceuticals International, Inc. - Pipeline by Stage of Development, 2014 8 Valeant Pharmaceuticals International, Inc. - Monotherapy Products in Pipeline, 2014 9 Valeant Pharmaceuticals International, Inc. - Partnered Products in Pipeline, 2014 10 Valeant Pharmaceuticals International, Inc. - Partnered Products/ Combination Treatment Modalities, 2014 11 Valeant Pharmaceuticals International, Inc. - Out-Licensed Products in Pipeline, 2014 12 Valeant Pharmaceuticals International, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2014 13 Valeant Pharmaceuticals International, Inc. - Phase III, 2014 14 Valeant Pharmaceuticals International, Inc. - Phase II, 2014 15 Valeant Pharmaceuticals International, Inc. - Phase I, 2014 16 Valeant Pharmaceuticals International, Inc. - Pipeline by Target, 2014 26 Valeant Pharmaceuticals International, Inc. - Pipeline by Route of Administration, 2014 27 Valeant Pharmaceuticals International, Inc. - Pipeline by Molecule Type, 2014 28 Valeant Pharmaceuticals International, Inc. - Pipeline Products by Mechanism of Action, 2014 29 Valeant Pharmaceuticals International, Inc. - Recent Pipeline Updates, 2014 30 Valeant Pharmaceuticals International, Inc. - Dormant Developmental Projects,2014 32 Valeant Pharmaceuticals International, Inc. - Discontinued Pipeline Products, 2014 33 Valeant Pharmaceuticals International, Inc., Other Locations 37 Valeant Pharmaceuticals International, Inc., Subsidiaries 38 Valeant Pharmaceuticals International, Inc., Key Manufacturing Facilities 42
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
